Tonix Pharmaceuticals receives up to $34M from US DoD for broad-spectrum antiviral development.
Tonix Pharmaceuticals secures up to $34M funding from US DoD to develop broad-spectrum antiviral. The deal with the Defense Threat Reduction Agency aims to create small molecule antivirals for military personnel's medical readiness in biological threat environments. This funding, part of the Pentagon's $2B budget for biological defense, supports the development of drugs beyond the "one bug, one drug" approach.
July 24, 2024
4 Articles